Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens

References

• Schlick W. The problems of treating atypical pneumonia. J Antimicrob Chemother 1993;31:C111–C120
   Google Scholar
• Plouffe JF. Importance of atypical pathogens of community-acquired pneumonia. Clin Infect Dis 2000;31:S35–S39
   PubMed Web of Science ®Google Scholar
• File Jr. TM. The epidemiology of respiratory tract infections. Semin Respir Infect 2000;15:184–94
   PubMedGoogle Scholar
• Marston BJ, Plouffe JF, File Jr. TM, et al. Incidence of community-acquired pneumonia requiring hospitalization. Arch Intern Med 1997;157:1709–18
   Google Scholar
• Bochud P-Y, Moser F, Erard P, et al. Community-acquired pneumonia. A prospective outpatient study. Medicine (Baltimore) 2001;80:75–87
   Google Scholar
• Falguera M, Sacristan O, Nogues A, et al. Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity. Arch Intern Med 2001;161:1866–72
   PubMed Web of Science ®Google Scholar
• Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989;11: 586–99
   Google Scholar
• Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730–54
   PubMed Web of Science ®Google Scholar
• Mandell LA, Bartlett JG, Dowell SF, File Jr. TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405–33
   Google Scholar
• Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infection 2002;8:214–21
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Danziger LH, Gotfried MH. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 2003;47:2450–7
   Google Scholar
• Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia – implications for practice guidelines. J Am Med Assoc 1998;279:1452–7
   PubMed Web of Science ®Google Scholar
• File Jr. TM, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965–72
   PubMed Web of Science ®Google Scholar
• Fogarty CM, Sullivan JG, Chattman MS, Williams RR, Kojak C, Rubin A. Once a day levofloxacin in the treatment of mild to moderate and severe community-acquired pneumonia in adults. Infect Dis Clin Pract 1998;7:400–7
   Web of Science ®Google Scholar
• Fogarty C, Siami G, Kohler R, et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin vs ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin/clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2003;38\(suppl 1):S16–S23
   Google Scholar
• Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752–60
   PubMed Web of Science ®Google Scholar
• Tennenberg AM, Khashab MM, Xiang JX, Wiesinger BA, Zadeikis N, Kahn JB. 750 mg, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Presented at the 99th International Coference of the American Thoracic Society, Seattle, WA, 2003
   Google Scholar
• Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community- acquired pneumonia. New Engl J Med 1997;336:243–50
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Morb Mortal Wkly Rep 1997;46:1–55
   PubMedGoogle Scholar
• Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001;33:492–503
   PubMed Web of Science ®Google Scholar
• Jacobs E. Serological diagnosis of Mycoplasma pneumoniae infections: a critical review of current procedures. Clin Infect Dis 1993;17\(suppl 1):S79–S82
   Google Scholar
• Altman DG. Practical statistics for medical research. Chapman and Hall, 1991
   Google Scholar
• Akpunonu B, Michaelis J, Tennenberg A, et al. Multicenter, postmarketing assessment of levofloxacin in the treatment of adults with community-acquired pneumonia. Clin Infect Dis 2003;38\(suppl 1):S5–S15
   Google Scholar
• Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996;101:508–15
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998–2002). Clin Infect Dis 2003;36:963–70
   PubMed Web of Science ®Google Scholar
• Schonwald S, Kuzman I, Oreskovic K, et al. Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome – a randomized study. Infection 1999;27: 198–202
   Google Scholar
• Socan M. Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course. J Chemother 1998;10:64–8
   PubMed Web of Science ®Google Scholar
• Sahm DF, Karlowsky JA, Kelly LJ, et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob Agents Chemother 2001;45:1037–42
   PubMed Web of Science ®Google Scholar
• Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001;119:1114–22
   Google Scholar
• Lister PD. Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002;44:43–9
   PubMed Web of Science ®Google Scholar
• Lacy MK, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999;43:672–7
   PubMed Web of Science ®Google Scholar
• Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003; 112:275–85
   PubMed Web of Science ®Google Scholar